We serve Chemical Name:tert-butyl 4-(2-amino-2-oxoethyl)piperazine-1-carboxylate CAS:77278-70-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:tert-butyl 4-(2-amino-2-oxoethyl)piperazine-1-carboxylate
CAS.NO:77278-70-7
Synonyms:2-(4-boc-piperazin-1-yl)-acetamide;(4-Boc-piperazin-1-yl)-acetamide
Molecular Formula:C11H21N3O3
Molecular Weight:243.30300
HS Code:2933599090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:384.7ºC at 760 mmHg
Density:1.136g/cm3
Index of Refraction:1.502
PSA:75.87000
Exact Mass:243.15800
LogP:0.60050
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-(4-boc-piperazin-1-yl)-acetamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-Boc-piperazin-1-yl)-acetamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(4-Boc-piperazin-1-yl)-acetamide Use and application,(4-Boc-piperazin-1-yl)-acetamide technical grade,usp/ep/jp grade.
Related News: Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. isobutyl 4-((dimethylamino)methyl)-5-hydroxy-2-methyl-1H-indole-3-carboxylate manufacturers “The most important thing to be considered while determining a CDMO competency is their technical knowledge along with adequate expertise to accomplish the drug development till commercial scaling. diethyl cis-3,6-dimethyl-3-hydroxycyclohexenyl phosphate suppliers Officials did, however, acknowledge that there’s growing evidence an extra jab may enhance the antibody response in immunocompromised people. Some small studies suggest up to 50% of people with no antibody response after the authorized regimen of two mRNA jabs developed a response after an additional dose, said CDC’s Sara Oliver, M.D. fluoro-acetic acid benzo[1,2,5]selenadiazol-4-ylamide vendor & factory.
